{"id":"1e32aa40-cef1-5892-9b62-911d9796c0c6","stable_key":"10629adf-a816-5b7b-82db-a76bfbb946f2:bg-imprime-needs-an-antibody-first","predicate":"enables","statement":"Imprime-induced anti-cancer functionality is dependent on immune complex formation with naturally-occurring anti-beta glucan antibodies, the formation of Imprime-antibody complexes activates complement primarily via the classical complement pathway and is opsonised by iC3b, immune complex binding depends upon Complement Receptor 3 and Fc gamma Receptor IIa eliciting phenotypic activation of and enhanced chemokine production by neutrophils and monocytes enabling these effector cells to kill antibody-opsonized tumour cells, and importantly these innate immune cell changes were not evident in subjects with low antibody levels but could be rescued with exogenous antibody supplementation.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"3eaa7366-f2c9-5b7e-8794-5757b8e00d31","mechanism_event_label":"This soluble glucan does nothing on its own; it has to be caught by an antibody the person already had.","subject":{"id":"afe6f619-e984-533b-b63a-83b4e77aab4f","slug":"anti-beta-glucan-antibodies","display_name":"Naturally occurring anti-beta-glucan IgG antibodies","entity_type_key":"protein"},"object":{"id":"a04b52d4-0af9-594a-bbda-51a16406d235","slug":"imprime-pgg","display_name":"Imprime PGG / BTH1677, a soluble yeast beta-(1->3)/(1->6)-glucan","entity_type_key":"drug"},"evidence_count":1,"mechanism_event":{"id":"3eaa7366-f2c9-5b7e-8794-5757b8e00d31","stable_key":"10629adf-a816-5b7b-82db-a76bfbb946f2:bg-imprime-needs-an-antibody-first-event","event_type":"biochemical_relationship","label":"This soluble glucan does nothing on its own; it has to be caught by an antibody the person already had.","description":"Imprime-induced anti-cancer functionality is dependent on immune complex formation with naturally-occurring anti-beta glucan antibodies, the formation of Imprime-antibody complexes activates complement primarily via the classical complement pathway and is opsonised by iC3b, immune complex binding depends upon Complement Receptor 3 and Fc gamma Receptor IIa eliciting phenotypic activation of and enhanced chemokine production by neutrophils and monocytes enabling these effector cells to kill antibody-opsonized tumour cells, and importantly these innate immune cell changes were not evident in subjects with low antibody levels but could be rescued with exogenous antibody supplementation.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"5146ad84-5cac-5c1c-848c-302bb17fa252","slug":"immune-complex-formation","display_name":"Formation of a glucan and antibody immune complex","entity_type_key":"cellular_process"},"role":"required_step","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"e95326ee-2dc4-52cb-9140-4f5b2f8121a6","slug":"classical-complement-pathway","display_name":"The classical complement pathway","entity_type_key":"cellular_process"},"role":"activated_pathway","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"04e0de91-27e8-50a3-9ad9-ff234a10cfc0","slug":"ic3b","display_name":"The complement fragment iC3b","entity_type_key":"protein_state"},"role":"opsonin","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"309b5460-2ec8-5c78-ada2-8637d6991433","slug":"cr3-complex","display_name":"Complement receptor 3 / CD11b-CD18","entity_type_key":"protein_complex"},"role":"required_receptor","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"e0454f71-07ca-500d-82bb-b794ffa3a25f","slug":"fcgr2a","display_name":"Fc gamma receptor IIa / FCGR2A","entity_type_key":"protein"},"role":"required_receptor","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""},{"entity":{"id":"7e39f8b2-8b39-5f3b-bb37-ca39a7f72221","slug":"tumour-cell-killing","display_name":"Killing of antibody-opsonised tumour cells by leukocytes","entity_type_key":"cellular_process"},"role":"enabled_process","stoichiometry":null,"state_label":"","sequence_order":5,"notes":""},{"entity":{"id":"afe6f619-e984-533b-b63a-83b4e77aab4f","slug":"anti-beta-glucan-antibodies","display_name":"Naturally occurring anti-beta-glucan IgG antibodies","entity_type_key":"protein"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":6,"notes":""},{"entity":{"id":"a04b52d4-0af9-594a-bbda-51a16406d235","slug":"imprime-pgg","display_name":"Imprime PGG / BTH1677, a soluble yeast beta-(1->3)/(1->6)-glucan","entity_type_key":"drug"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":7,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/glucan-research/27812183.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"949fc5939bec2e3fab259b6b6161fba8cdd7779c7efa0261a1e7dbf1cab111cf\", \"start_char\": 0, \"end_char\": 1493, \"text_sha256\": \"949fc5939bec2e3fab259b6b6161fba8cdd7779c7efa0261a1e7dbf1cab111cf\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Whole blood from healthy human subjects with antibody-depleted and antibody-supplemented conditions","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Imprime PGG in whole blood across a range of naturally occurring anti-beta-glucan antibody levels","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Ex vivo whole blood rather than treated patients. The antibody dependence is demonstrated both by absence in low-antibody donors and by rescue with added antibody.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair.","comparator":null,"unit":null,"notes":"","entity":{"slug":"beta-glucan","display_name":"Beta-glucan","entity_type_key":"chemical_species"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"This soluble glucan does nothing on its own; it has to be caught by an antibody the person already had.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[bg-p27812183] Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation. (2016). https://pubmed.ncbi.nlm.nih.gov/27812183/ DOI: 10.1371/journal.pone.0165909","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Whole blood, neutrophil and monocyte","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"c1f5e2dc-5993-5d7d-bb9b-99f27b362771","evidence_kind":"source_excerpt","locator":"Lines 268-279","start_line":268,"end_line":279,"excerpt":"### bg-imprime-needs-an-antibody-first\nImprime-induced anti-cancer functionality is dependent on immune complex formation with naturally-occurring anti-beta glucan antibodies, the formation of Imprime-antibody complexes activates complement primarily via the classical complement pathway and is opsonised by iC3b, immune complex binding depends upon Complement Receptor 3 and Fc gamma Receptor IIa eliciting phenotypic activation of and enhanced chemokine production by neutrophils and monocytes enabling these effector cells to kill antibody-opsonized tumour cells, and importantly these innate immune cell changes were not evident in subjects with low antibody levels but could be rescued with exogenous antibody supplementation.\nCondition category: normal\nnutrient_topic: Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair.\nplain_language: This soluble glucan does nothing on its own; it has to be caught by an antibody the person already had.\norganism: Human\ntissue_or_cell_type: Whole blood, neutrophil and monocyte\nexperimental_model: Whole blood from healthy human subjects with antibody-depleted and antibody-supplemented conditions\nlimitations: Ex vivo whole blood rather than treated patients. The antibody dependence is demonstrated both by absence in low-antibody donors and by rescue with added antibody.\nexposure: Imprime PGG in whole blood across a range of naturally occurring anti-beta-glucan antibody levels\nevidence_span: {\"source_cache\": \"artifacts/glucan-research/27812183.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"949fc5939bec2e3fab259b6b6161fba8cdd7779c7efa0261a1e7dbf1cab111cf\", \"start_char\": 0, \"end_char\": 1493, \"text_sha256\": \"949fc5939bec2e3fab259b6b6161fba8cdd7779c7efa0261a1e7dbf1cab111cf\"}\n[bg-p27812183] Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation. (2016). https://pubmed.ncbi.nlm.nih.gov/27812183/ DOI: 10.1371/journal.pone.0165909","model_system":"Whole blood from healthy human subjects with antibody-depleted and antibody-supplemented conditions","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [bg-p27812183] Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation. (2016). https://pubmed.ncbi.nlm.nih.gov/27812183/ DOI: 10.1371/journal.pone.0165909","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"74dc223d-8289-57bf-a731-d220fa017c1e","stable_key":"import-10629adf-a816-5b7b-82db-a76bfbb946f2","title":"Beta-glucan: a structural family rather than an agent, what decides whether a bound glucan actually signals, the complement route that a cereal and a yeast preparation share, and the unequal human evidence behind each (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"7c62f2d2f8d99b650e6dc26a505b0f053ae1c8bdb38099d4dfc0771f65287461","revision_id":"a53bb794-0a4b-525d-9cf7-22b46a5403b0","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}